These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30156056)

  • 1. Effects of metformin and alogliptin on body composition in people with type 2 diabetes.
    Takeshita Y; Kita Y; Kato KI; Kanamori T; Misu H; Kaneko S; Takamura T
    J Diabetes Investig; 2019 May; 10(3):723-730. PubMed ID: 30156056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
    Kaku K; Sumino S; Katou M; Nishiyama Y; Kinugawa Y
    Diabetes Obes Metab; 2017 Mar; 19(3):463-467. PubMed ID: 27891757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
    Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
    Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
    Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
    Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
    Rosenstock J; Wilson C; Fleck P
    Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
    Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
    Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
    Rosenstock J; Rendell MS; Gross JL; Fleck PR; Wilson CA; Mekki Q
    Diabetes Obes Metab; 2009 Dec; 11(12):1145-52. PubMed ID: 19758359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E; Ellis GC; Wilson CA; Fleck PR
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
    Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
    J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
    Kim JM; Kim SS; Kim JH; Kim MK; Kim TN; Lee SH; Lee CW; Park JY; Kim ES; Lee KJ; Choi YS; Kim DK; Kim IJ
    Diabetes Metab J; 2020 Feb; 44(1):67-77. PubMed ID: 31339011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
    Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
    Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
    Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
    Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
    Pan C; Li W; Zeng J; Li C; Yang J; Ji Q; Lu J; Lyu X; Li X; Qu S; Xu X; Xue Y; Li L; Jiang Z; Zheng B; Bu R; Han P; Liu Y; Liu J; Peng Y; Liu X; Liu Z; Yan L; Lei M; Li X; Song Q; Shi B; Gu W; Li Z
    Zhonghua Nei Ke Za Zhi; 2015 Nov; 54(11):949-53. PubMed ID: 26759214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.